用户名: 密   码:
注册 | 忘记密码?
专利信息
查询条件 展开筛选条件
所有数据
排序 翻到页码
标题标题2专利权人发明人附图摘要摘要2优先权号IPC专利类型
首页123456下页尾页300161 条记录, 当前第1/30017页。
公开号 公开日 申请号 申请日
1. GB2527802A 2016-1-6 GB20140011839 2014-7-2
专利标题:Tablet with differentiated absorption 法律状态
专利权人OLIMED LTD [GB];
A tablet with differentiated oromucosal and enteric absorption comprises glutathione and/or its acetyl or proprionyl form; micro-granules each formed of an inner core of L-cysteine and/or its dimer L-Cystine, and an outer gastro-resistant coating consisting of a lipophilic matrix. The glutathione and/or its acetyl or proprionyl form may be present in the range of about 15% to about 30% w/w by weight of the tablet, and the L-cysteine and/or its dimer L-Cystine may be present in the range of about...


2. EP2961383A1 2016-1-6 EP20140712793 2014-2-28
专利标题:SUSPENSION FOR ORAL ADMINISTRATION COMPRISING AMORPHOUS TOLVAPTAN 法律状态


3. EP2962685A1 2016-1-6 EP20150174276 2015-6-29
专利标题:ORALLY DISINTEGRATING FORMULATIONS OF TADALAFIL 法律状态
The present invention relates to an orally disintegrating pharmaceutical formulation comprising tadalafil or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient.


4. EP2962684A1 2016-1-6 EP20150174255 2015-6-29
专利标题:ORALLY DISINTEGRATING FORMULATIONS OF TADALAFIL 法律状态
The present invention relates to an orally disintegrating pharmaceutical formulation comprising tadalafil or a pharmaceutically acceptable salt thereof; mannitol and one or more pharmaceutically acceptable excipient.


5. GB2527726A 2016-1-6 GB20140000647 2014-1-15
专利标题:Topical composition 法律状态
A topical composition comprising silver sulfadiazine, preferably 0.5wt% to 1.5wt%; an acrylates/beheneth-n methacrylate copolymer wherein n is an integer between 20 and 30, preferably 0.03wt% to 2.0wt%; a surfactant mixture which comprises a sorbitan ester and a sorbital ester (sorbityl ester), wherein the mean number of carbon atoms of the hydrophobe of the sorbitan ester is greater than that of the sorbitol ester, preferably 0.5wt% to 8wt%; and an acceptable diluent or carrier, is provided. Pr...


6. EP2962988A1 2016-1-6 EP20150169531 2015-5-28
专利标题:COMPOSITIONS, PREPARATION FOR PRODUCTION OF CHLORIDE DIOXIDE AND FINAL PRESENTATION FORMS 法律状态
"COMPOSITIONS, PREPARATION FOR PRODUCTION OF CHLORIDE DIOXIDE AND FINAL PRESENTATION FORMS", more specifically, consists of the compositions and preparation for production of chloride dioxide with sundry purposes, more precisely a combination of balanced mixes of inorganic salts (citric acid + Sodium Chlorite and tartaric acid + sodium bicarbonate), proportionally balanced and packed individually or pressed in tablet form, produced through preparation or chemical route subdivided in 3 phases: (I...


7. EP2961390A1 2016-1-6 EP20140707724 2014-2-27
专利标题:PHARMACEUTICAL FORMULATIONS COMPRISING QUETIAPINE AND ESCITALOPRAM 法律状态


8. EP2963040A1 2016-1-6 EP20150163741 2010-9-2
专利标题:SUBSTITUTED XANTHINE DERIVATIVES 法律状态
This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related comp...


9. EP2963028A1 2016-1-6 EP20150175884 2010-5-26
专利标题:PIPERAZINE DERIVATIVES AND THEIR PHARMACEUTICAL USE 法律状态
专利权人ATIR HOLDING S A [LU];
Novel piperazine derivatives of the formula Ia: comprising a dibenzofurane moiety are privided herein, as well as pharmaceutical compositions comprising same and therapeutic uses thereof to treat disorders such as central nervous disorders.


10. EP2962686A1 2016-1-6 EP20150180143 2006-2-28
专利标题:DOSAGE FORM CONTAINING OXYCODONE AND NALOXONE 法律状态
专利权人EURO CELTIQUE SA [LU];
A combination of oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain, wherein 80 mg up to 160 mg of oxycodone or a pharmaceutical acceptable salt thereof are administered orally per day together with naloxone or a pharmaceutically acceptable salt thereof, wherein the weight ratio of oxycodone:naloxone is 2: 1, and wherein oxycodone or a pharmaceutically acceptable salt thereof and naloxone or a pharma...



首页123456下页尾页300161 条记录, 当前第1/30017页。

下载范围

下载第 条记录。

下载内容

题录信息 专利全文